Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

The Washington University trial comes as part of a larger platform study, which hopes to understand whether the disease can ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...

Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral ...

Eli Lilly (LLY) is set to announce Q4 earnings results, with analysts expecting positive growth driven by key drugs and new product launches.

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

The weight loss injection Mounjaro is a new treatment that can now be delivered to customers' homes by a new clinic service offered by Morrisons.

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...